Study guide
7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs
Key Takeaways Explain This Topic AI
Mobitz II block and complete heart block are infranodal, produce an unreliable escape rhythm and are indications for permanent pacing; Mobitz I rarely needs a pacemaker.
Amiodarone is a class III agent causing thyroid dysfunction, pulmonary fibrosis, hepatitis, corneal microdeposits and slate-grey skin, and it potentiates warfarin and digoxin.
Flecainide is a class Ic agent contraindicated after myocardial infarction and in structural heart disease because of proarrhythmic mortality demonstrated in the CAST trial.
Last updated: September 2026
- 4. Bradyarrhythmias & Conduction Blocks
- Sick Sinus Syndrome (Sinus Node Dysfunction)
Intrinsic dysfunction of the sinoatrial node, commonly due to fibrodegenerative changes in elderly individuals. Manifests as inappropriate sinus bradycardia, sinus pauses (>3 seconds), sinoatrial exit block, or the tachycardia-bradycardia syndrome (paroxysmal atrial tachyarrhythmias alternating with profound sinus pauses). Definitive management requires a permanent pacemaker (dual-chamber, DDDR) combined with antiarrhythmic/rate-controlling medication for the tachycardic episodes.
Atrioventricular (AV) Blocks
First-Degree AV Block: Constant, prolonged PR interval >200 ms (5 small squares). Every P wave is conducted to the ventricles. Anatomical site is almost always intra-nodal. Usually benign, asymptomatic, and does not require pacing unless accompanied by bifascicular block.
Second-Degree AV Block - Mobitz Type I (Wenckebach): Progressive PR interval prolongation from beat to beat until a single P wave fails to conduct (dropped QRS). The cycle then resets. The greatest increment in PR prolongation occurs between the first and second conducted beats of the cycle. Occurs at the level of the AV node itself. Commonly seen during high vagal tone (athletes, sleep) or in acute inferior myocardial infarction. Generally carries a benign prognosis; pacemaker is rarely indicated unless severely symptomatic.
Second-Degree AV Block - Mobitz Type II: Constant, fixed PR intervals with intermittent, non-conducted P waves (e.g., 2:1, 3:1, or 4:1 conduction). The defect lies distal to the AV node within the His bundle or bundle branches ( infranodal ). Carries an ominous prognosis with high risk of sudden progression to complete heart block, syncope (Adams-Stokes attacks), and sudden cardiac death. Absolute indication for permanent pacemaker insertion , regardless of symptoms.
Third-Degree (Complete) AV Block: Complete absence of AV conduction; atria and ventricles depolarise independently (complete AV dissociation with regular P-P intervals and regular, slower R-R intervals). If the escape rhythm originates high in the junction, QRS is narrow (40–55 bpm); if infranodal/ventricular, QRS is broad and slow (20–40 bpm). Clinical examination reveals variable intensity of the first heart sound (S1) and intermittent, prominent cannon 'a' waves in the jugular venous pulse (caused by right atrial systole against a closed tricuspid valve). Requires urgent temporary pacing followed by definitive dual-chamber permanent pacemaker insertion.
5. Vaughan-Williams Classification of Antiarrhythmic Drugs
Class Mechanism of Action Exemplar Drugs Electrophysiological Effects Key Clinical Indications & Caveats
Ia Fast Na+ channel blockade (moderate) + K+ channel blockade Procainamide, Disopyramide, Quinidine Prolongs action potential duration (APD) and QTc interval; slows phase 0 Pre-excited AF, ventricular arrhythmias. Risk of Torsades de Pointes. Disopyramide has marked anticholinergic and negative inotropic effects.
Ib Fast Na+ channel blockade (mild/rapid kinetics) Lidocaine, Mexiletine Shortens APD; preferentially binds ischaemic tissue Acute ventricular tachyarrhythmias post-MI. Ineffective in supraventricular arrhythmias. CNS toxicity (tremor, seizures).
Ic Fast Na+ channel blockade (potent, slow kinetics) Flecainide, Propafenone Marked slowing of conduction velocity; no effect on APD; widens QRS Paroxysmal AF cardioversion/pill-in-the-pocket, WPW. Strictly contraindicated in ischaemic or structural heart disease (CAST trial proarrhythmia).
II Competitive beta-adrenergic receptor antagonism Bisoprolol, Metoprolol, Atenolol, Esmolol Blunts Phase 4 spontaneous depolarisation; slows SA/AV node conduction Rate control in AF, post-MI mortality reduction, suppression of ventricular ectopy. Contraindicated in acute decompensated heart failure, severe asthma, AV block.
III Potassium channel blockade (I_Kr inhibition) Amiodarone, Sotalol, Dronedarone Prolongs repolarization, APD, and effective refractory period; lengthens QTc Broad-spectrum (AF rhythm control, stable VT/VF). Amiodarone exhibits Class I–IV actions. Monitoring required: LFTs, TFTs (hypo/hyperthyroidism), CXR (pulmonary fibrosis), corneal microdeposits, slate-grey skin discoloration.
IV Non-dihydropyridine L-type Ca2+ channel blockade Verapamil, Diltiazem Slows AV nodal conduction velocity and prolongs refractory period Paroxysmal SVT termination, rate control in AF with preserved LVEF. Contraindicated in HFrEF, WPW with AF, and co-administration with beta-blockers.
Misc Adenosine A1 receptor agonism / Na+/K+ ATPase inhibition Adenosine, Digoxin, Magnesium sulphate Adenosine hyperpolarizes AV node; Digoxin augments central vagal tone Adenosine: first-line acute termination of AVNRT/orthodromic AVRT. Digoxin: AF rate control in sedentary/HFrEF. Magnesium: Torsades de Pointes.
Sinus Node Disease and Reversible Bradycardia
Sick sinus syndrome (sinus node dysfunction) covers inappropriate sinus bradycardia, sinus pauses, sinoatrial exit block and the tachy-brady syndrome , in which paroxysmal atrial fibrillation alternates with symptomatic pauses on termination. It is a disease of fibrotic degeneration in older patients, and the tachy-brady variant is the classic reason a patient needs both a pacemaker and rate-controlling or anticoagulant therapy — the pacemaker permits drug treatment of the tachycardia that would otherwise be limited by the pauses.
Before committing any patient to a permanent device, exclude reversible causes:
Reversible cause Clue
Drugs (beta blockers, verapamil, diltiazem, digoxin, ivabradine, donepezil) Recent initiation or dose increase; renal impairment
- Hypothyroidism Bradycardia with slow-relaxing reflexes, raised TSH
- Hyperkalaemia Tented T waves, broad QRS, sine wave
- Raised intracranial pressure Cushing reflex: bradycardia with hypertension
- Inferior myocardial infarction Vagally mediated, usually atropine-responsive, often transient
- Hypothermia, obstructive sleep apnoea, athletic training Context
- Infiltration: sarcoidosis, amyloidosis, Lyme carditis Young patient with unexplained high-grade block
Unexplained complete heart block in a patient under 60 should prompt consideration of cardiac sarcoidosis or Lyme carditis , both of which can be reversible with treatment and are commonly missed.
Acute Management and Pacing
Acute symptomatic bradycardia with adverse features (shock, syncope, myocardial ischaemia, heart failure) is treated with atropine 500 micrograms intravenously, repeated to a maximum of 3 mg , then second-line measures such as isoprenaline, adrenaline infusion or transcutaneous pacing while transvenous pacing is arranged. Atropine is ineffective in infranodal block, because the lesion is below the level of vagal influence — a Mobitz II or complete heart block with a broad escape rhythm should go straight to pacing rather than repeated atropine.
Digoxin Toxicity
Digoxin is not in the Vaughan-Williams classification but generates a disproportionate number of examination questions. Toxicity causes nausea, confusion, xanthopsia (yellow-green visual haloes), and almost any arrhythmia , classically atrial tachycardia with block or bidirectional ventricular tachycardia. Hypokalaemia, hypomagnesaemia and hypercalcaemia potentiate it , as does renal impairment and co-prescription of amiodarone, verapamil, spironolactone or macrolides. The reverse-tick ST depression of digoxin effect is a normal therapeutic finding and does not indicate toxicity. Treatment is digoxin-specific antibody fragments (DigiFab) for life-threatening arrhythmia or a potassium above 5.0 mmol/L in acute poisoning; calcium should be avoided in digoxin-associated hyperkalaemia.